EFFICACY OF "NEO INULIN"
IN THE COMPLEX TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
Published on Acta Biomedica Scientifica
https://www.actabiomedica.ru
Авторы:
Katamanova E.V.
Kazakova P.V.
Kudaeva I.V.
Kuks A.N.
Ushakova O.V.
OUTLINE
Diabetes mellitus (DM) is one of the most serious medical, social and economic health problems in all countries of the world. The incidence of diabetes doubles every 10-15 years, becoming a non-infectious epidemic. Therefore, it is extremely important to search for new medications that help to normalise glycaemia, prevent diabetes complications, and improve the quality of life of patients. Neo Inulin", which has hypoglycaemic, antioxidant, hepatoprotective and angioprotective effects, can be referred to such means.
The aim of the study: to evaluate the effectiveness of "Neo inulin" in the complex treatment of patients with type 2 diabetes mellitus.
Materials and methods. The study included 18 women (mean age - 64.5 ± 8.7 years, mean weight - 77.8 ± 11.4 kg) and 3 men (mean age - 54.6 ± 12.4 years, mean weight - 114 ± 40.2 kg). The mean duration of type 2 diabetes mellitus was 11.0 (7.0-12.0) years. "Neo Inulin" was prescribed 2 capsules per day for 12 weeks in the complex of basic therapy of diabetes mellitus. To assess the effectiveness of therapy, the study of health-related quality of life, blood biochemical examination (glycated haemoglobin), clinical minimum (OAC, OAM, ECG, blood glucose), functional characteristics of tissue blood flow were investigated, ankle-brachial index (ABI) was determined. Statistical processing of the results was performed using Statistica 6.0 software package (StatSoft Inc., USA). The value of 0.05 was taken as the critical level of statistical significance.
RESULTS
Statistically significant differences in the indices of all scales of health-related quality of life in patients in the groups before and after treatment with "Neo Inulin", including total physical and mental components, were revealed. Improvement of microcirculatory mechanisms functioning was noted, which is confirmed by statistically significant increase of LPI (on the right - 1.0 and 0.8; on the left - 0.9 and 0.8 respectively; p < 0.05) and coefficient of variation of microcirculatory flow (9.2 and 8.3 respectively; p < 0.05). Normalisation of glycated haemoglobin level was achieved in 57.1% of cases (12 patients).
CONCLUSION
Treatment with "Neo-Inulin" for up to three months in the complex therapy of type 2 diabetes mellitus allows to normalise some microcirculation parameters: statistically significant increase of LPI and coefficient of variation of microcirculation flow, as well as statistically significant decrease of glycated haemoglobin and fasting glucose.
The use of a treatment regimen including "Neo-Inulin" promotes treatment efficacy and improves the quality of life of patients with type 2 DM, resulting in higher levels of psychosocial adaptation and treatment efficacy.